THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Gary Raskob to Heparin, Low-Molecular-Weight

This is a "connection" page, showing publications Gary Raskob has written about Heparin, Low-Molecular-Weight.
Connection Strength

2.219
  1. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003 Dec; 124(6 Suppl):379S-385S.
    View in: PubMed
    Score: 0.223
  2. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001 Nov 20; 135(10):858-69.
    View in: PubMed
    Score: 0.194
  3. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001 Sep 10; 161(16):1952-60.
    View in: PubMed
    Score: 0.191
  4. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats. Oncologist. 2021 01; 26(1):e8-e16.
    View in: PubMed
    Score: 0.181
  5. Heparin and low molecular weight heparin for treatment of acute pulmonary embolism. Curr Opin Pulm Med. 1999 Jul; 5(4):216-21.
    View in: PubMed
    Score: 0.164
  6. Hirudin versus heparin and low-molecular-weight heparin: and the winner is... J Lab Clin Med. 1998 Sep; 132(3):171-4.
    View in: PubMed
    Score: 0.155
  7. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis. 1998; 28 Suppl 3:8-16.
    View in: PubMed
    Score: 0.148
  8. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15; 378(7):615-624.
    View in: PubMed
    Score: 0.148
  9. Low molecular weight heparin for the prevention and treatment of venous thromboembolism. Curr Opin Pulm Med. 1996 Jul; 2(4):305-10.
    View in: PubMed
    Score: 0.133
  10. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013 Jul; 11(7):1287-94.
    View in: PubMed
    Score: 0.108
  11. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med. 2009 Aug; 122(8):762-769.e3.
    View in: PubMed
    Score: 0.083
  12. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007 Jan; 120(1):72-82.
    View in: PubMed
    Score: 0.069
  13. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 Dec; 119(12):1062-72.
    View in: PubMed
    Score: 0.069
  14. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):401S-428S.
    View in: PubMed
    Score: 0.059
  15. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group. Arch Intern Med. 2000 Jan 24; 160(2):229-36.
    View in: PubMed
    Score: 0.043
  16. Preoperative vs postoperative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement. Arch Intern Med. 1999 Jan 25; 159(2):137-41.
    View in: PubMed
    Score: 0.040
  17. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence. Arch Intern Med. 1997 Nov 10; 157(20):2317-21.
    View in: PubMed
    Score: 0.037
  18. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):289-94.
    View in: PubMed
    Score: 0.035
  19. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. An economic perspective. Arch Intern Med. 1997 Feb 10; 157(3):298-303.
    View in: PubMed
    Score: 0.035
  20. Low molecular weight heparin, heparin, and warfarin. Curr Opin Hematol. 1995 Sep; 2(5):372-9.
    View in: PubMed
    Score: 0.031
  21. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993 Nov 04; 329(19):1370-6.
    View in: PubMed
    Score: 0.028
  22. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):454S-545S.
    View in: PubMed
    Score: 0.019
  23. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):287S-310S.
    View in: PubMed
    Score: 0.015
  24. Hemorrhagic complications of anticoagulant treatment. Chest. 2001 Jan; 119(1 Suppl):108S-121S.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES